Shopping Cart
- Remove All
Your shopping cart is currently empty
Bupivacaine (AH-250) is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 50 mg | $33 | In Stock | |
| 100 mg | Preferential | In Stock | |
| 1 mL x 10 mM (in DMSO) | $52 | In Stock |
| Description | Bupivacaine (AH-250) is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain. |
| In vitro | Bupivacaine inhibits NMDA receptor-mediated synaptic transmission in the dorsal horn of the spinal cord, a key area in central sensitization[1]. It affects the voltage dependency of channel activation and steady-state inactivation by shifting the membrane potential of half-maximal activation/inactivation toward more negative potentials. SCN5A channels are slightly sensitive to Bupivacaine in their inactivated state (IC50=2.18±0.16 μM)[2]. Additionally, Bupivacaine reversibly inhibits the SK2 channel in a dose-dependent manner with an IC50 of 16.5 µM[3]. |
| Synonyms | Exparel, Bupivacaina, Anekain, AH-250, AH250, AH 250 |
| Molecular Weight | 288.43 |
| Formula | C18H28N2O |
| Cas No. | 38396-39-3 |
| Smiles | CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C |
| Relative Density. | 1.032 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (86.68 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.